Accelerating Safety Data:

Higher-Throughput Toxicology Studies via Minimally Invasive Telemetry

Tuesday, November 17th, 2026 at 12:00 – 12:55 PM

Grand Oaks Ballroom, Level 2, Suite N

Introduced by Brian Roche (Charles River Laboratories), this session will focus on a telemetry solution that supports both refinement through minimally invasive approaches and reduction through integrated study designs, aligning with the 3Rs, as drug development embraces New Approach Methodologies (NAMs).

The presentation will examines the shift from invasive intraperitoneal implant placement to miniaturized subcutanesous implants, culminating in a truly minimally invasive alternative. As emka’s miniature implants require minimal surgical disruption, animal recovery times are drastically reduced while generating high-quality cardiovascular physiological signals. This acceleration allows for higher-throughput, high-turnover studies that reduce timelines and costs.

Featuring insights from an ongoing study with Envol Biomedical, Dr. Espinosa will outline how these smaller implants can be leveraged to optimize safety pharmacology strategies with regard to animal welfare, study design, and timelines, while simultaneously capturing vital safety endpoints.

Register to save your seat

Speaker Spotlight:

DR. BRIAN ROCHE, PhD, ATS – CHARLES RIVER LABORATORIES

Dr. Brian Roche, General Manager at Charles River’s Kansas site, has more than 20 years’ experience in preclinical drug development through multiple roles with a focus on research from early pharmacology through GLP safety pharmacology studies. In his previous role as the Executive Director of Global Safety Pharmacology, he provided scientific expertise and leadership on behalf of the Global Safety Pharmacology portfolio, including strategy development and best practice alignment across sites.

DR. RANEIR ESPINOSA – CHARLES RIVER LABORATORIES

Dr. Reinier Espinosa, MD is Director of Translational Science at Envol Biomedical, leading the design and execution of non-human primate studies that bridge nonclinical research with clinical development. He brings over 10 years of experience across clinical medicine, Phase I–IV clinical trials, preclinical NHP research, and translational science.

Trained neurosurgeon and diplomate in intensive care medicine, Dr. Espinosa has a deep expertise in CNS-related procedures and advanced surgical models.

He provides hands-on surgical expertise in advanced drug delivery and surgical platforms, including intrathecal and MRI-guided CNS dosing, cardiovascular telemetry, , endovascular procedures, microperfusion systems, and perioperative recovery management. He partners closely with sponsors to deliver scientifically rigorous, compliant, and clinically relevant data that accelerate development and support regulatory decision-making.